Showing 3021-3030 of 4063 results for "".
- New Licensing Agreement Accelerates the Development of IACTA Pharmaceuticals’ Novel Dry Eye Disease and Allergic Conjunctivitis Treatments in China and Southeast Asiahttps://modernod.com/news/new-licensing-agreement-accelerates-the-development-of-iacta-pharmaceuticals-novel-dry-eye-disease-and-allergic-conjunctivitis-treatments-in-china-and-southeast-asia/2478088/IACTA Pharmaceuticals and Zhaoke Ophthalmology Pharmaceutical (ZKO), a Hong Kong-based pharmaceutical company, announced they have entered into a definitive license agreement on the licensing of two of the company’s products, IC 265 for dry eye and IC 270 fo
- Pepcid As a Coronavirus Remedy? Trump’s $21-Million Gamble Fizzledhttps://modernod.com/news/pepcid-as-a-coronavirus-remedy-trumps-21-million-gamble-fizzled/2478070/As the coronavirus began its deadly march through the world, two well-respected American doctors identified a possible but seemingly unlikely remedy: Pepcid, the heartburn medication found on drugstore shelves everywhere, according to an Associated
- Aurinia Prices $200 Million Public Offering of Common Shareshttps://modernod.com/news/aurinia-prices-200-million-public-offering-of-common-shares/2478066/Aurinia Pharmaceuticals, a late-stage clinical biopharmaceutical company focused on advancing voclosporin in multiple indications, announced the pricing of its underwritten public offering of 13,333,334 common shares. The company is currently developing the investig
- Norlase Announces CE Mark Approval for LEAF Green Laserhttps://modernod.com/news/norlase-announces-ce-mark-approval-for-leaf-green-laser/2478045/Norlase announced that it has been granted the CE Mark approval for the LEAF, a first in class, fiberless green laser for the treatment of retina and glaucoma diseases. The CE Mark follows the recent FDA 510(k) market clearance of the LEAF and ISO 13485:2016 certification of Norlase’s medical dev
- Ocutrx Says It Will Deliver World’s First 5G AR/XR Medical Specific Platform in 2021https://modernod.com/news/ocutrx-says-it-will-deliver-worlds-first-5g-ar-xr-medical-specific-platform-in-2021/2477980/Ocutrx Vision Technologies announced plans to deliver the first AR headsets specific for medical applications providing connectivity from AT&T and using 5G products from Qualcomm Technologies. Ocutrx is building its AR/XR medical device, the Oculenz headset, for patient use; and a seco
- Samsung Bioepis Announces 24-Week Interim Results From a Phase 3 Trial of Ranibizumab Biosimilarhttps://modernod.com/news/samsung-bioepis-announces-24-week-interim-results-from-a-phase-3-trial-of-ranibizumab-biosimilar/2477785/Samsung Bioepis announced that the primary endpoints have been met in the randomized, double-masked, phase 3 trial comparing the efficacy, safety and immunogenicity of SB11, a ranibizumab biosimilar candidate, to reference ranibizumab in patients with wet age-related macular degeneration (AMD).</
- AMA Issues Guidance to Physicians on Using COVID-19 Antibody Testshttps://modernod.com/news/ama-issues-guidance-to-physicians-on-using-covid-19-antibody-tests/2477783/As new serology tests for COVID-19 rapidly come to the market, the American Medical Association (AMA) is cautioning physicians about using these tests to make healthcare decisions for individual patients, according to a FierceHealthcare
- Trump Administration Aims to Replenish Strategic National Stockpile to Brace for 2nd COVID-19 Wavehttps://modernod.com/news/trump-administration-aims-to-replenish-strategic-national-stockpile-to-brace-for-2nd-covid-19-wave/2477777/The Trump administration is moving to replenish a national stockpile of medical supplies to prepare for a potential second surge of COVID-19 or another respiratory illness, including adding critical care drugs, according to a FierceHealthcare
- NIH Panel Issues COVID-19 Treatment Guidelines Highlighting Lack of Data for Antiviral, Immunomodulatory Therapies Under Investigationhttps://modernod.com/news/nih-panel-issues-covid-19-treatment-guidelines-highlighting-lack-of-data-for-antiviral-immunomodulatory-therapies-under-investigation/2477628/A panel of medical experts convened by the US National Institutes of Health (NIH) has drafted treatment guidelines for COVID-19, saying there is not enough evidence for several therapeutic options currently under investigation. However, the guidance, which focuses on antivirals as well as host mo
- FDA Quickly Authorizes Its 2nd Blood Filtering Device for COVID-19https://modernod.com/news/fda-quickly-authorizes-its-2nd-blood-filtering-device-for-covid-19/2477585/Shortly after granting an emergency authorization to Terumo BCT’s blood filtering device for COVID-19, the FDA did the same for CytoSorbents’ system, according to a FierceBiotech